Annual report pursuant to Section 13 and 15(d)

Segment Information - Schedule of Segment Information (Details)

v3.24.1.u1
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Revenues $ 0 $ 0
Gross profit 0 0
Total Operating income (19,846) (3,149)
Depreciation and amortization 1,452 2
Interest income (expense), net 2,250 468
Total Net income after provision for income taxes (7,812) 10,992
Discontinued operations    
Segment Reporting Information [Line Items]    
Revenues 3,795 39,611
Gross profit (197) 7,619
Total Operating income 10,438 8,395
Depreciation and amortization 96 555
Interest income (expense), net (181) (957)
Total Net income after provision for income taxes 9,283 2,972
Continuing and discontinued operation    
Segment Reporting Information [Line Items]    
Revenues 3,795 39,611
Gross profit (197) 7,619
Total Operating income (9,408) 5,246
Depreciation and amortization 1,548 557
Interest income (expense), net 2,069 (489)
Total Net income after provision for income taxes (7,812) 10,992
Biotechnology    
Segment Reporting Information [Line Items]    
Revenues 0 0
Gross profit 0 0
Total Operating income (19,846) (3,149)
Depreciation and amortization 1,452 2
Interest income (expense), net 2,250 468
Total Net income after provision for income taxes $ (17,095) $ 8,020